Recent investigations on retatrutide, a dual activator for incretin hormone and gastric inhibitory polypeptide, indicate promising findings in managing obesity and type 2 glucose intolerance. Preliminary data from clinical trials point to notable diminutions in body bulk and bettered glucose regulation. Ongoing research is focused on long-term safe